BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Epocrates Inc. Files for $75 Million IPO


7/19/2010 6:26:56 AM

SAN MATEO, Calif., Jul 16, 2010 (BUSINESS WIRE) -- Epocrates, Inc., a leading provider of mobile drug reference tools and interactive services to healthcare professionals and the healthcare industry, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.

J.P. Morgan Securities Inc. and Piper Jaffray & Co. are serving as joint book-running managers for the proposed offering. William Blair & Company, L.L.C. and JMP Securities LLC are acting as co-managers. The number of shares to be sold and the price range for the proposed offering have not yet been determined.

A registration statement relating to Epocrates' securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The proposed offering will be made only by means of a prospectus. Once the prospectus is available, a copy may be obtained from J.P. Morgan Securities Inc., c/o Broadridge Financial Solutions, 1155 Long Island Ave, Edgewood, NY, 11717, or by calling 1-866-803-9204, or from Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by calling 1-800-747-3924 or sending an email to prospectus@pjc.com.

About Epocrates

Epocrates is a leading provider of mobile drug reference tools and interactive services to healthcare professionals and the healthcare industry. Epocrates' active user network currently has more than one million healthcare professionals, including more than 40 percent of U.S. physicians. Most commonly used on mobile devices at the point of care, the company's products and services help healthcare professionals make more informed prescribing decisions, enhance patient safety and improve practice productivity.

SOURCE: Epocrates, Inc.

Investor and Press Contact Epocrates, Inc. Erica Sniad Morgenstern, 650-227-6907 pr@epocrates.com

Copyright Business Wire 2010

Read at Reuters
Read at RTT News
Read at Wall Street Journal
Read at BioSpace.com
Read at Private Equity Hub

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES